CN114681350B - Detergent composition containing lysozyme - Google Patents
Detergent composition containing lysozyme Download PDFInfo
- Publication number
- CN114681350B CN114681350B CN202210557814.XA CN202210557814A CN114681350B CN 114681350 B CN114681350 B CN 114681350B CN 202210557814 A CN202210557814 A CN 202210557814A CN 114681350 B CN114681350 B CN 114681350B
- Authority
- CN
- China
- Prior art keywords
- lysozyme
- denture
- cleanser composition
- myricetin
- denture cleanser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
- A61Q11/02—Preparations for deodorising, bleaching or disinfecting dentures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention relates to a denture cleanser composition, wherein the weight ratio of active ingredients of lysozyme to mountain Jiang Suhe myricetin is 1: (1-3): (1-3). Compared with the commercial preparation, the denture cleanser has the advantages of simple preparation method and reasonable compatibility, and three active ingredients can generate synergistic effect while playing respective roles, thereby obviously inhibiting various bacteria and fungi on dentures. In addition, lysozyme, alpinetin and myricetin are natural in source, and have no toxic and side effects.
Description
Technical Field
The invention relates to the field of daily chemicals, in particular to a denture cleanser.
Background
The denture is one of the main restoration methods of the prior dentition defect and the dentition defect, but the use of the denture leads the original microecological balance of the oral cavity to be destroyed, the saliva flow velocity between the denture base and the mucous membrane and the denture in the bearing area is reduced, the flow is reduced, the oxidation-reduction potential value and the oxygen supply condition are changed, and simultaneously the denture base affects the physiological self-cleaning function of the oral cavity. These changes in microenvironment increase the adhesion of the causative bacteria of dental caries and periodontal disease and increase the chances of caries and periodontal disease. Dental prostheses with poor hygiene are prone to oral malodour due to the spoilage of their surface and plaque; the mucous membrane in the bearing area is stimulated by long-term plaque and its products (toxins) on the tissue side of the denture, causing local inflammatory changes, severe cases will develop denture inflammation and candidiasis. Therefore, denture cleaning is of great clinical importance in killing pathogens, preventing local inflammation and systemic disease.
Candida albicans is a common symbiotic fungus in the oral cavity of healthy people, and can cause candida stomatitis due to conditional pathogenicity. The detection of candida albicans in the oral cavity is affected by various factors, mainly including denture restoration, host age and the like, wherein the host age factor is represented by the increase of the detection rate of candida albicans in the oral cavity of the aged, and the aged is the main crowd wearing movable dentures. The influence of denture restoration on oral candida field planting in healthy old people is researched by scholars, and the detection rate and the detection intensity of candida albicans in the oral cavity of the old people with denture restoration are obviously enhanced compared with those without denture.
The caries caused by candida albicans is mainly caused by the acid production of candida albicans, the acid production causes the reduction of local pH value, the demineralization of the tooth or tooth root surface is caused, meanwhile, the reduction of the pH value can activate acid proteinase, phosphatase and collagenase of candida, promote tissue destruction, thereby causing the invasion of candida and facilitating the adhesion of candida albicans. Collagenase produced by candida albicans can not only cause caries, but also cause dissolution of collagen in periodontal tissues, leading to severe periodontitis.
Common denture cleaning methods include mechanical, microwave irradiation, chemical, and the like, with chemical methods being the most widely used. The chemical cleaning agent mainly comprises hypochlorite, peroxides, acids and enzymes according to the composition and action mechanism. The enzyme detergent mainly comprises proteolytic enzyme, yeast hydrolase, lipase, amylase, dextranase and the like. The principle of action is to decompose glycoprotein, mucin and mucopolysaccharide in the bacterial plaque by utilizing enzyme to destroy the formation of bacterial plaque and calculus. The degradation effect of enzyme on denture constituent materials is the slightest, but the cleaning effect is limited by single use, so the cleanser and other components are combined into a compound formulation to improve the cleaning effect.
At present, the cleaning agent for soaking the false teeth in the market has stronger corrosiveness and unsatisfactory antibacterial effect. Therefore, there is a need to develop a denture cleanser which is natural in source, free of toxic and side effects and remarkable in antibacterial effect, and can replace a commercial product.
Lysozyme is also called muramidase or N-acetylmuramidase hydrolase, and is an alkaline enzyme capable of hydrolyzing mucopolysaccharide in pathogenic bacteria. The bacterial lysis is mainly achieved by breaking the beta-1, 4 glycosidic bond between the N-acetylmuramic acid and N-acetylglucosamine in the cell wall, which breaks down the insoluble mucopolysaccharide of the cell wall into soluble glycopeptides, resulting in the escape of the broken cell wall contents. Lysozyme can also bind directly to negatively charged viral proteins, forming double salts with DNA, RNA, apoproteins, inactivating the virus. Lysozyme has antibacterial, antiinflammatory, antiviral effects, and is widely used in food, feed, and medicine industries because lysozyme can specifically act on the cell wall of target microorganism.
The chemical name of alpinetin is (S) -7-hydroxy-5-methoxy flavanone, which is the main active ingredient of semen Alpiniae Katsumadai, and is widely distributed in plants of Myristica genus of Zingiberaceae and Populus genus of Salicaceae. The alpinetin is mainly derived from roots or seeds of Alpinia katsumadai, such as Alpinia katsumadai, alnus tsumadai, polygonum, scutellaria baicalensis, etc. Recently, as a result of intensive studies on flavonoid compounds, it has been found that alpinetin has various pharmacological actions. Alpinetin has various degrees of inhibition on platelet aggregation caused by arachidonic acid, collagen, adenosine diphosphate and ristocetin. In vitro antiviral pharmacodynamic experiments show that the alpinetin has good antiviral effects on respiratory viruses, herpesviruses, adenoviruses, human immunodeficiency viruses, hepatitis viruses and the like, and in addition, the alpinetin also has the effects of resisting oxidation and rheumatism.
Myricetin is a natural plant extract, and widely exists in fruits and vegetables such as onion and strawberry, and the content of Myricetin and myricetin in red wine accounts for 20% -50% of the total flavonoid content. Myricetin has various biological activities such as oxidation resistance, inflammation resistance, tumor resistance, aging resistance, blood sugar reduction, lipid reduction, sedation, blood vessel abnormality inhibition, cardiovascular protection and the like. Recent studies have shown that myricetin can reduce blood glucose by increasing insulin sensitivity, improving glycogen metabolism, insulin-like action, etc. Experiments prove that myricetin can improve insulin resistance and reduce blood sugar by improving insulin sensitivity.
At present, the application of combination of lysozyme and mountain Jiang Suhe myricetin to denture cleaners has not been reported yet.
Disclosure of Invention
The invention aims to solve the technical problem of providing the denture cleanser which can effectively clean dentures, has no toxic or side effect and good antibacterial effect and is natural in active ingredient source.
The invention solves the problems by adopting the technical scheme that a denture cleanser composition is provided, wherein the weight ratio of active ingredients of lysozyme to mountain Jiang Suhe myricetin is 1: (1-3): (1-3).
Preferably, in the detergent composition, the weight ratio of lysozyme to mountain Jiang Suhe myricetin is 1: (1-2): (1-2).
More preferably, in the detergent composition, the weight ratio of lysozyme to mountain Jiang Suhe myricetin is 1:2:1.
preferably, the lysozyme is extracted from egg white.
Preferably, the detergent composition further comprises pharmaceutically acceptable auxiliary materials.
More preferably, the pharmaceutically acceptable auxiliary materials are selected from one or more of acidic substances, alkaline substances, filling agents, flavoring agents and lubricating agents.
Most preferably, the acidic substance is tartaric acid or citric acid; the alkaline substance is sodium carbonate or sodium bicarbonate; the filler is lactose, mannitol or xylitol; the flavoring agent is betaine or aspartame; the lubricant is magnesium stearate or silicon dioxide.
Preferably, the detergent composition is in the form of a tablet, an aqueous solution, etc., more preferably an effervescent tablet.
The invention also provides application of the detergent composition in inhibiting fungus generation in false teeth.
Preferably, the fungus is candida albicans.
The invention has the positive beneficial effects that: surprisingly, through repeated experiments, the invention surprisingly found that the combination of lysozyme and mountain Jiang Suhe myricetin has a synergistic effect on inhibiting fungi on dentures. Compared with the commercial preparation, the denture cleanser has the advantages of simple preparation method and reasonable compatibility, and three active ingredients can generate synergistic effect while playing respective roles, thereby obviously inhibiting various bacteria and fungi on dentures. In addition, lysozyme, alpinetin and myricetin are natural in source, and have no toxic and side effects.
Detailed Description
The present invention will be further described with reference to examples, but the embodiments of the present invention are not limited thereto. The experimental methods used in the following examples are conventional methods unless otherwise specified. The lysozyme used in examples and test examples was lysozyme extracted from egg white.
Example 1 effervescent tablet T1 containing lysozyme
Mixing 200g lysozyme with 120g tartaric acid, 120g sodium bicarbonate, 50g lactose and 5g aspartame, granulating with absolute ethyl alcohol, drying, adding 5g magnesium stearate, and pressing into 100 tablets, wherein each effervescent tablet has a weight of 5g.
Example 2 effervescent tablet T2 containing alpinetin
200g of alpinetin, 120g of tartaric acid, 120g of sodium bicarbonate, 50g of lactose and 5g of aspartame are uniformly mixed, granulated by absolute ethyl alcohol, dried, added with 5g of magnesium stearate and pressed into 100 tablets, and each effervescent tablet has the weight of 5g.
Example 3 Myricetin-containing effervescent tablet T3
200g of myricetin, 120g of tartaric acid, 120g of sodium bicarbonate, 50g of lactose and 5g of aspartame are uniformly mixed, granulated by absolute ethyl alcohol, dried, added with 5g of magnesium stearate and pressed into 100 tablets, and each effervescent tablet has the weight of 5g.
Example 4 effervescent tablet T4 containing lysozyme, mountain Jiang Suhe myricetin (lysozyme: alpinetin: myricetin=1:1:1)
66.6g of lysozyme, 66.6g of alpinetin and 66.6g of myricetin are uniformly mixed with 120g of tartaric acid, 120g of sodium bicarbonate, 50g of lactose and 5g of aspartame, the mixture is granulated by absolute ethyl alcohol, 5g of magnesium stearate is added after drying, and 100 tablets are prepared by pressing, wherein the weight of each effervescent tablet is 5g.
Example 5 effervescent tablet T5 containing lysozyme, mountain Jiang Suhe myricetin (lysozyme: alpinetin: myricetin=1:1:2)
50g of lysozyme, 50g of alpinetin and 100g of myricetin are uniformly mixed with 120g of tartaric acid, 120g of sodium bicarbonate, 50g of lactose and 5g of aspartame, the mixture is granulated by absolute ethyl alcohol, 5g of magnesium stearate is added after drying, and 100 tablets are prepared by pressing, wherein the weight of each effervescent tablet is 5g.
Example 6 effervescent tablet T6 containing lysozyme, mountain Jiang Suhe Myricetin (lysozyme: alpinetin: myricetin=1:2:1)
50g of lysozyme, 100g of alpinetin and 50g of myricetin are uniformly mixed with 120g of tartaric acid, 120g of sodium bicarbonate, 50g of lactose and 5g of aspartame, the mixture is granulated by absolute ethyl alcohol, 5g of magnesium stearate is added after drying, and 100 tablets are prepared by pressing, wherein the weight of each effervescent tablet is 5g.
Test example 1 cleaning Effect of denture cleanser of the present invention on Candida albicans biofilm
1.1 cultivation of Candida albicans biofilm
Thawing frozen candida albicans strains, inoculating the candida albicans strains into a glucose agar medium, and culturing the candida albicans strains in a carbon dioxide incubator at 37 ℃ for 24 hours for resuscitation. Single colonies were picked and transferred to 10ml of yeast extract peptone glucose medium and placed in a temperature control culture shaker at 30℃for overnight culture. Collecting thallus, centrifugally washing with phosphate buffer solution for 2 times, re-suspending with modified RPMI 1640 culture medium, and counting with a blood cell counting plate under an inverted microscope to adjust the concentration of thallus to 1×10 per milliliter 6 And (3) bacterial cells. 200 μl of the bacterial liquid with the concentration is taken to be placed in the micro-holes of a 96-hole micro-culture plate, and is placed in a carbon dioxide incubator at 37 ℃ for culturing for 24 hours, so as to form the candida albicans biomembrane.
1.2 cleaning treatment of denture cleaners
The formed biofilm was discarded, and each well was washed 3 times with 200. Mu.l of phosphate buffer to remove non-adherent bacteria. The effervescent tablets T1-T6 of examples 1-6 were taken and each tablet was dissolved in 150ml of sterile distilled water at 40℃respectively, and 200. Mu.l of the solution was added to the biofilm after complete dissolution of the effervescent tablets. Each denture cleanser was repeatedly soaked in 5 biofilm-attached wells, while positive control groups (biofilm soaked with sterile distilled water) and negative control groups (no biofilm) were set. Each group of denture cleaners was soaked for 15min, the cleaners were discarded, and washed 3 times with phosphate buffer to remove residual cleaners.
1.3 quantification of Candida albicans biofilm Activity
The change in metabolic activity of the biofilm was measured using the methyltetrazate (XTT) reduction method. 100 μl of the modified RPMI 1640 medium and 50 μl of the XTT-menaquinone mixture were added to each well, including a positive control group and a negative control group, and the wells were incubated at 37deg.C in a carbon dioxide incubator for 2 hours in the absence of light, and the absorbance value (A value) of each well was measured on a microplate reader at 490 nm.
1.4 quantification of Candida albicans biofilm biomass
The crystal violet content assay was used to quantify the biomass of the biofilm. The medium and XTT-menaquinone mixture in each well was discarded and the phosphate buffer was washed 1 time. After the biofilm was air dried, 100. Mu.l of 0.5% (w/v) crystal violet solution was added to each well and allowed to act for 5min. The crystal violet solution was then discarded and the phosphate buffer washed 3 times to remove excess dye. Adding 100 μl of 95% ethanol into each hole of the dyed biological film for decolorizing, repeatedly blowing and sucking for 1min to completely dissolve crystal violet on the biological film, transferring the ethanol dissolved with crystal violet into another clean 96-hole microplate, and measuring absorbance value (A value) of each hole on an enzyme-labeled instrument by selecting 570nm wavelength.
1.5 statistical analysis
The percentage of candida albicans biofilm activity and biomass reduction after immersion in denture cleanser was calculated according to the following formula: reduction rate= [1- (A) Experimental group -A Negative control group )/(A Positive control group -A Negative control group )]*100%. The test results are shown in Table 1.
TABLE 1 Effect of the effervescent tablets of the invention on Candida albicans biofilm Activity and biomass
The test results show that the activity and biomass of candida albicans biological films are reduced to different degrees after the denture cleanser of the invention is used in various proportions, and the denture cleanser of the invention has obvious effect in inhibiting denture fungi. Particularly, under the condition that the total amount of active ingredients is kept unchanged, compared with the denture cleanser (T4-T6) which is singly used and contains lysozyme, alpinetin or myricetin, the denture cleanser (T1-T3) which is used by the invention and contains the lysozyme and the alpinetin is used, the activity and biomass of candida albicans biological film are obviously reduced, and the combined use of the lysozyme and the alpinetin is proved to produce a synergistic effect, and the use amount of antibacterial ingredients is reduced. Among them, the denture cleanser with the weight ratio of lysozyme to mountain Jiang Suhe myricetin of 1:2:1 is most remarkable in effect, resulting in an unexpected excellent effect.
Claims (7)
1. A denture cleanser composition, characterized in that the weight ratio of active ingredients lysozyme to mountain Jiang Suhe myricetin is 1: (1-2): (1-2).
2. The denture cleanser composition according to claim 1, wherein the weight ratio of lysozyme to mountain Jiang Suhe myricetin is 1:2:1.
3. the denture cleanser composition of claim 1, further comprising a pharmaceutically acceptable adjuvant.
4. The denture cleanser composition of claim 3, wherein the pharmaceutically acceptable excipients are selected from one or more of acidic substances, basic substances, fillers, flavoring agents, lubricants.
5. The denture cleanser composition of claim 4, wherein the acidic is tartaric acid or citric acid; the alkaline substance is sodium carbonate or sodium bicarbonate; the filler is lactose, mannitol or xylitol; the flavoring agent is betaine or aspartame; the lubricant is magnesium stearate or silicon dioxide.
6. The denture cleanser composition of claim 1, wherein the cleanser composition is in the form of a tablet or an aqueous solution.
7. The denture cleanser composition of claim 6, wherein the cleanser composition is in the form of an effervescent tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210557814.XA CN114681350B (en) | 2021-02-06 | 2021-02-06 | Detergent composition containing lysozyme |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110176065.1A CN112870104B (en) | 2021-02-06 | 2021-02-06 | Denture cleanser composition |
| CN202210557814.XA CN114681350B (en) | 2021-02-06 | 2021-02-06 | Detergent composition containing lysozyme |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110176065.1A Division CN112870104B (en) | 2021-02-06 | 2021-02-06 | Denture cleanser composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114681350A CN114681350A (en) | 2022-07-01 |
| CN114681350B true CN114681350B (en) | 2023-06-13 |
Family
ID=76056245
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110176065.1A Active CN112870104B (en) | 2021-02-06 | 2021-02-06 | Denture cleanser composition |
| CN202210557814.XA Active CN114681350B (en) | 2021-02-06 | 2021-02-06 | Detergent composition containing lysozyme |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110176065.1A Active CN112870104B (en) | 2021-02-06 | 2021-02-06 | Denture cleanser composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN112870104B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2028570A1 (en) * | 1989-10-27 | 1991-04-28 | Richard S. Carpenter | Antimicrobial method and formulation employing type ii endoglycosidase and antimicrobial agent |
| CN102697771A (en) * | 2012-06-26 | 2012-10-03 | 上海中医药大学 | New application of alpinetin |
| CN105053174A (en) * | 2015-09-17 | 2015-11-18 | 邯郸学院 | Preparation method and application of plant source complex preservative |
| CN105213250A (en) * | 2015-09-08 | 2016-01-06 | 上海应用技术学院 | A kind of Compositional type natural antibacterial agent and preparation method thereof and the application in cosmetics |
| CN107582420A (en) * | 2017-10-31 | 2018-01-16 | 陕西爱骨医疗股份有限公司 | A kind of preparation method of denture cleaning solution |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11147792B2 (en) * | 2017-05-15 | 2021-10-19 | Axial Therapeutics, Inc. | Inhibitors of microbially induced amyloid |
| CN110859757A (en) * | 2019-11-22 | 2020-03-06 | 广州康云生物科技有限公司 | Lysozyme-containing mouthwash effervescent tablet and preparation method thereof |
-
2021
- 2021-02-06 CN CN202110176065.1A patent/CN112870104B/en active Active
- 2021-02-06 CN CN202210557814.XA patent/CN114681350B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2028570A1 (en) * | 1989-10-27 | 1991-04-28 | Richard S. Carpenter | Antimicrobial method and formulation employing type ii endoglycosidase and antimicrobial agent |
| CN102697771A (en) * | 2012-06-26 | 2012-10-03 | 上海中医药大学 | New application of alpinetin |
| CN105213250A (en) * | 2015-09-08 | 2016-01-06 | 上海应用技术学院 | A kind of Compositional type natural antibacterial agent and preparation method thereof and the application in cosmetics |
| CN105053174A (en) * | 2015-09-17 | 2015-11-18 | 邯郸学院 | Preparation method and application of plant source complex preservative |
| CN107582420A (en) * | 2017-10-31 | 2018-01-16 | 陕西爱骨医疗股份有限公司 | A kind of preparation method of denture cleaning solution |
Non-Patent Citations (3)
| Title |
|---|
| "Characterization of the binding of flavanone hesperetin with chicken egg lysozyme using spectroscopic techniques: effect of pH on the binding";Atanu Singha Roy 等;《J Incl Phenom Macrocycl Chem》;第84卷;第21页 * |
| "药物与溶菌酶相互作用的研究进展";刘淑鑫 等;《中南药学》;第09卷(第09期);第687页 * |
| "黄芩苷对白色念珠菌生物膜形成的体外抑制作用";李福明 等;《海峡药学》;第28卷(第03期);第224页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114681350A (en) | 2022-07-01 |
| CN112870104B (en) | 2022-06-24 |
| CN112870104A (en) | 2021-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2333768C2 (en) | Ferment-containing composition of improved stability for oral cavity | |
| CN107281013B (en) | Toothpaste for removing tooth stain and inhibiting dental plaque | |
| RU2355420C2 (en) | Toothpaste containing lactulose, betaine, chondroitin sulphate and enzymes: papain, lysocim, ribonuclease and lidase | |
| CN103987371B (en) | Oral care compositions | |
| RU2381021C2 (en) | Liposome containing tooth paste | |
| JPH08502970A (en) | Antibacterial mouthwash | |
| TWI733123B (en) | Prebiotic oral care compositions containing an alkyl glycoside | |
| CN110257297A (en) | Lactobacillus paracasei PC-01 and its application for being used to promote oral health of one plant of separation | |
| CN102151233A (en) | Antibacterial dentifrice exhibiting enhanced antiplaque and breath freshening properties | |
| CN107811890A (en) | A kind of oral cavity caring toothpaste composition | |
| US20030099602A1 (en) | D-tagatose as an anti-biofilm agent | |
| KR100599934B1 (en) | Composition for preventing or treating periodontal disease | |
| CN109453044A (en) | A kind of multiple-effect type polishing of teeth cream | |
| US7189351B2 (en) | D-tagatose as an anti-biofilm agent | |
| CN108186384A (en) | A kind of mouthwash and preparation method thereof | |
| EP2146683B1 (en) | Use of an aqueous grape seed extract combined with at least one fluorine salt to combat the formation or accumulation of dental biofilm and compositions comprising said combination | |
| JP4661593B2 (en) | Novel lactic acid bacteria, biostimulated lactic acid bacteria preparations, and preventive and therapeutic agents for infectious diseases in living | |
| Lamfon | Denture biofilm and dentureassociated stomatitis, A literature review | |
| CN114681350B (en) | Detergent composition containing lysozyme | |
| KR100519477B1 (en) | Periodontal disease prevention and treatment composition containing trichromic acid, urodessoxycholine acid derivative and milky skin extract | |
| CN107485584A (en) | A kind of oral care composition | |
| CN114159500A (en) | Hyaluronic acid essential oil composition for nourishing and repairing oral cavity and application thereof | |
| Ghelichli | Formulation of new herbal Salvadora toothpaste with antidecay, wound healing and caring tooth and Periodontal diseases | |
| Le Bars et al. | Denture Plaque Management of Denture-Related Stomatitis | |
| KR20170123613A (en) | Opportunistic infectious microorganism Double microorganism preparation for long-term inhibition or prevention of symptoms of infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |